- Home
- SPH vs PHVS Comparison
SPH vs PHVS Comparison
Compare SPH & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPH
- PHVS
- Stock Information
- Founded
- SPH 1945
- PHVS 2015
- Country
- SPH United States
- PHVS Switzerland
- Employees
- SPH N/A
- PHVS N/A
- Industry
- SPH Other Specialty Stores
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- SPH Consumer Discretionary
- PHVS Health Care
- Exchange
- SPH Nasdaq
- PHVS Nasdaq
- Market Cap
- SPH 1.2B
- PHVS 980.9M
- IPO Year
- SPH 1996
- PHVS 2021
- Fundamental
- Price
- SPH $18.57
- PHVS $22.99
- Analyst Decision
- SPH Sell
- PHVS Buy
- Analyst Count
- SPH 1
- PHVS 6
- Target Price
- SPH $17.00
- PHVS $37.17
- AVG Volume (30 Days)
- SPH 162.7K
- PHVS 59.1K
- Earning Date
- SPH 08-07-2025
- PHVS 08-13-2025
- Dividend Yield
- SPH 6.99%
- PHVS N/A
- EPS Growth
- SPH N/A
- PHVS N/A
- EPS
- SPH 1.46
- PHVS N/A
- Revenue
- SPH $1,424,243,000.00
- PHVS N/A
- Revenue This Year
- SPH $10.99
- PHVS N/A
- Revenue Next Year
- SPH N/A
- PHVS N/A
- P/E Ratio
- SPH $12.75
- PHVS N/A
- Revenue Growth
- SPH 4.02
- PHVS N/A
- 52 Week Low
- SPH $15.20
- PHVS $11.51
- 52 Week High
- SPH $22.24
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- SPH 49.89
- PHVS 67.31
- Support Level
- SPH $18.05
- PHVS $17.63
- Resistance Level
- SPH $18.70
- PHVS $26.33
- Average True Range (ATR)
- SPH 0.39
- PHVS 1.70
- MACD
- SPH 0.05
- PHVS 0.65
- Stochastic Oscillator
- SPH 68.27
- PHVS 65.24
About SPH Suburban Propane Partners L.P.
Suburban Propane Partners LP distributes propane, fuel oil, and other refined fuels to customers in the East Coast and West Coast regions of the United States. Other operations include natural gas and electricity marketing in the deregulated New York and Pennsylvania markets. The company operates in three segments: Propane; Fuel Oil and Refined Fuels; and Natural Gas and Electricity. It generates maximum revenue from Propane segment.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.